NasdaqGS - Nasdaq Real Time Price USD

Treace Medical Concepts, Inc. (TMCI)

5.74

-0.12

(-2.05%)

At close: May 30 at 4:00:00 PM EDT

Wall Street Analysts See a 41.11% Upside in Treace Medical Concepts (TMCI): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 41.1% in Treace Medical Concepts (TMCI). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks 19 days ago

TMCI
-2.05%
Treace Medical Concepts, Inc. (NASDAQ:TMCI) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates

Last week, you might have seen that Treace Medical Concepts, Inc. ( NASDAQ:TMCI ) released its first-quarter result to...

Simply Wall St. 21 days ago

TMCI
-2.05%
Treace Medical Concepts First Quarter 2025 Earnings: EPS Beats Expectations

Treace Medical Concepts ( NASDAQ:TMCI ) First Quarter 2025 Results Key Financial Results Revenue: US$52.6m (up 2.9...

Simply Wall St. 22 days ago

TMCI
-2.05%
Treace Medical Concepts Inc (TMCI) Q1 2025 Earnings Call Highlights: Strategic Innovations and ...

Treace Medical Concepts Inc (TMCI) reports revenue growth and improved EBITDA, while navigating market competition and preparing for new product launches.

GuruFocus.com 24 days ago

TMCI
-2.05%
Treace Medical Concepts (TMCI) Reports Q1 Loss, Tops Revenue Estimates

Treace Medical Concepts (TMCI) delivered earnings and revenue surprises of 19.35% and 1.05%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks 24 days ago

TMCI
-2.05%
Treace Medical Concepts: Q1 Earnings Snapshot

PONTE VEDRA, Fla. AP) — Treace Medical Concepts Inc. TMCI) on Thursday reported a loss of $15.9 million in its first quarter.

Associated Press Finance 24 days ago

TMCI
-2.05%
Treace Medical Concepts Reports First Quarter 2025 Financial Results

PONTE VEDRA, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today reported financial results for the first quarter ended March 31, 2025. Recent Highlights Generated revenue of $52.6 million in first quarter 2025 representing growth of 3% over

GlobeNewswire 24 days ago

TMCI
-2.05%
Treace to Report First Quarter 2025 Financial Results on May 8, 2025

PONTE VEDRA, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that it will release financial results for the first quarter 2025 after the close of trading on Thursday, May 8, 2025. Company management will host a conference cal

GlobeNewswire last month

TMCI
-2.05%
Treace Announces Upcoming Board Chair Transition

PONTE VEDRA, Fla., April 07, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that its Board of Directors has appointed John. T. Treace, Chief Executive Officer and Founder of Treace, as the Chairman of the Board to be effective immediately f

GlobeNewswire last month

TMCI
-2.05%
Treace Announces Clinical Study Data Demonstrating Positive Lapiplasty® and Adductoplasty® Outcomes at the 2025 ACFAS Annual Scientific Conference

PONTE VEDRA, Fla., March 28, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced the presentation of updated interim data for the ALIGN3D™ and Mini3D™ Lapiplasty® clinical studies, as well as the first presentation of the MTA3D™ Adductoplasty® c

GlobeNewswire 2 months ago

TMCI
-2.05%
Treace Highlights New Innovations at the 2025 ACFAS Annual Scientific Conference

Expands market-leading position with new best-in-class bunion technologiesPONTE VEDRA, Fla., March 25, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced new technology innovations featured at the 2025 American College of Foot and Ankle Surgeon

GlobeNewswire 2 months ago

TMCI
-2.05%
John Treace Spends US$524k On Treace Medical Concepts Stock

Those following along with Treace Medical Concepts, Inc. ( NASDAQ:TMCI ) will no doubt be intrigued by the recent...

Simply Wall St. 2 months ago

TMCI
-2.05%
Treace Medical Concepts Full Year 2024 Earnings: EPS Beats Expectations

Treace Medical Concepts ( NASDAQ:TMCI ) Full Year 2024 Results Key Financial Results Revenue: US$209.4m (up 12% from FY...

Simply Wall St. 2 months ago

TMCI
-2.05%
Treace Medical Concepts Inc (TMCI) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ...

Treace Medical Concepts Inc (TMCI) reports a 10.4% revenue increase and unveils new products, setting the stage for future growth despite a slight dip in gross margin.

GuruFocus.com 3 months ago

TMCI
-2.05%
Treace Medical Concepts (TMCI) Reports Q4 Loss, Tops Revenue Estimates

Treace Medical Concepts (TMCI) delivered earnings and revenue surprises of 66.67% and 0.16%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 3 months ago

TMCI
-2.05%
Treace Medical Concepts: Q4 Earnings Snapshot

The Ponte Vedra, Florida-based company said it had a loss of 1 cent per share. The results topped Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 3 cents per share.

Associated Press Finance 3 months ago

TMCI
-2.05%
Treace Medical Concepts Reports Fourth Quarter and Full-Year 2024 Financial Results

PONTE VEDRA, Fla., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today reported financial results for the fourth quarter and full year ended December 31, 2024. Recent Highlights Revenue of $68.7 million in fourth quarter 2024 increased 10% over s

GlobeNewswire 3 months ago

TMCI
-2.05%
Insider Stock Buying Reaches US$7.31m On Treace Medical Concepts

Quite a few insiders have dramatically grown their holdings in Treace Medical Concepts, Inc. ( NASDAQ:TMCI ) over the...

Simply Wall St. 3 months ago

TMCI
-2.05%
Treace to Report Fourth Quarter and Full-Year 2024 Financial Results on February 27, 2025

PONTE VEDRA, Fla., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that it will release financial results for the fourth quarter and full year of 2024 after the close of trading on Thursday, February 27, 2025. Company management wil

GlobeNewswire 3 months ago

TMCI
-2.05%
Why Treace Medical Concepts (TMCI) Is Rallying Today

Treace Medical Concepts (TMCI) is jumping 7.5% after investment bank BTIG upgraded the shares to Buy from Neutral. Why BTIG Upgraded the Shares Treace provides technology that facilitates Lapiplasty bunion surgery and related midfoot deformities. The company recently introduced a new technique called the SpeedAkin™ Anatomic Compression Implant. The “implant broadens the procedural versatility of […]

Insider Monkey 3 months ago

TMCI
-2.05%

Performance Overview

Return	TMCI	S&P 500 (^GSPC)
YTD	-22.85%	+0.51%
1-Year	-0.17%	+12.92%
3-Year	-65.67%	+42.17%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Treace Medical Concepts, Inc. (TMCI)

Wall Street Analysts See a 41.11% Upside in Treace Medical Concepts (TMCI): Can the Stock Really Move This High?

Treace Medical Concepts, Inc. (NASDAQ:TMCI) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates

Treace Medical Concepts First Quarter 2025 Earnings: EPS Beats Expectations

Treace Medical Concepts Inc (TMCI) Q1 2025 Earnings Call Highlights: Strategic Innovations and ...

Treace Medical Concepts (TMCI) Reports Q1 Loss, Tops Revenue Estimates

Treace Medical Concepts: Q1 Earnings Snapshot

Treace Medical Concepts Reports First Quarter 2025 Financial Results

Treace to Report First Quarter 2025 Financial Results on May 8, 2025

Treace Announces Upcoming Board Chair Transition

Treace Announces Clinical Study Data Demonstrating Positive Lapiplasty® and Adductoplasty® Outcomes at the 2025 ACFAS Annual Scientific Conference

Treace Highlights New Innovations at the 2025 ACFAS Annual Scientific Conference

John Treace Spends US$524k On Treace Medical Concepts Stock

Treace Medical Concepts Full Year 2024 Earnings: EPS Beats Expectations

Treace Medical Concepts Inc (TMCI) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ...

Treace Medical Concepts (TMCI) Reports Q4 Loss, Tops Revenue Estimates

Treace Medical Concepts: Q4 Earnings Snapshot

Treace Medical Concepts Reports Fourth Quarter and Full-Year 2024 Financial Results

Insider Stock Buying Reaches US$7.31m On Treace Medical Concepts

Treace to Report Fourth Quarter and Full-Year 2024 Financial Results on February 27, 2025

Why Treace Medical Concepts (TMCI) Is Rallying Today

Performance Overview